Literature DB >> 30357756

C-MYC, HIF-1α, ERG, TKT, and GSTP1: an Axis in Prostate Cancer?

L Boldrini1, R Bartoletti2, M Giordano3, F Manassero4, C Selli2, M Panichi5, L Galli6, F Farci3, P Faviana3.   

Abstract

To analyze putative biomarkers for prostate cancer (PCA) characterization, the second leading cause of cancer-associated mortality in men. Quantification of the expression level of c-myc and HIF-1α was performed in 72 prostate cancer specimens. A cohort of 497 prostate cancer patients from The Cancer Genome Atlas (TCGA) database was further analyzed, in order to test our hypothesis. We found that high c-myc level was significantly associated with HIF-1α elevated expression (p = 0.008) in our 72 samples. Statistical analysis of 497 TCGA prostate cancer specimens confirmed the strong association (p = 0.0005) of c-myc and HIF-1α expression levels, as we found in our series. Moreover, we found high c-myc levels significantly associated with low Glutatione S-transferase P1 (GSTP1) expression (p = 0.01), with high Transketolase (TKT) expression (p < 0.0001). High TKT levels were found in TCGA samples with low GSTP1 mRNA (p < 0.0001), as shown for c-myc, and with ERG increased expression (p = 0.02). Finally, samples with low GSTP1 expression displayed higher ERG mRNA levels than samples with high GSTP1 score (p < 0.0001), as above shown for c-myc. Our study emphasizes the notion of a potential value of HIF-1α and c-myc as putative biomarkers in prostate cancer; moreover TCGA data analysis showed a putative crosstalk between c-myc, HIF-1α, ERG, TKT, and GSTP1, suggesting a potential use of this axis in prostate cancer.

Entities:  

Keywords:  C-myc; GSTP1, TKT, ERG; HIF-1α; Prostate cancer

Mesh:

Substances:

Year:  2018        PMID: 30357756     DOI: 10.1007/s12253-018-0479-4

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  47 in total

Review 1.  The Myc/Max/Mad network and the transcriptional control of cell behavior.

Authors:  C Grandori; S M Cowley; L P James; R N Eisenman
Journal:  Annu Rev Cell Dev Biol       Date:  2000       Impact factor: 13.827

2.  Association of ERG and TMPRSS2-ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels.

Authors:  Alba Font-Tello; Núria Juanpere; Silvia de Muga; Marta Lorenzo; José A Lorente; Lluis Fumado; Laia Serrano; Sergio Serrano; Josep Lloreta; Silvia Hernández
Journal:  Prostate       Date:  2015-05-04       Impact factor: 4.104

3.  Myc posttranscriptionally induces HIF1 protein and target gene expression in normal and cancer cells.

Authors:  Megan R Doe; Janice M Ascano; Mandeep Kaur; Michael D Cole
Journal:  Cancer Res       Date:  2011-12-20       Impact factor: 12.701

Review 4.  MYC in oncogenesis and as a target for cancer therapies.

Authors:  Ami Albihn; John Inge Johnsen; Marie Arsenian Henriksson
Journal:  Adv Cancer Res       Date:  2010       Impact factor: 6.242

Review 5.  Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability.

Authors:  Robert G Bristow; Richard P Hill
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

6.  Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations.

Authors:  Asa Karlsson; Sylvie Giuriato; Flora Tang; Jingly Fung-Weier; Göran Levan; Dean W Felsher
Journal:  Blood       Date:  2002-11-27       Impact factor: 22.113

7.  HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth.

Authors:  Kelly L Covello; James Kehler; Hongwei Yu; John D Gordan; Andrew M Arsham; Cheng-Jun Hu; Patricia A Labosky; M Celeste Simon; Brian Keith
Journal:  Genes Dev       Date:  2006-03-01       Impact factor: 11.361

8.  TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.

Authors:  Outi R Saramäki; Anna E Harjula; Paula M Martikainen; Robert L Vessella; Teuvo L J Tammela; Tapio Visakorpi
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

Review 9.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

Review 10.  Hypoxia-inducible factors, stem cells, and cancer.

Authors:  Brian Keith; M Celeste Simon
Journal:  Cell       Date:  2007-05-04       Impact factor: 41.582

View more
  6 in total

Review 1.  The Expression of Proto-Oncogene ETS-Related Gene (ERG) Plays a Central Role in the Oncogenic Mechanism Involved in the Development and Progression of Prostate Cancer.

Authors:  Ealia Khosh Kish; Muhammad Choudhry; Yaser Gamallat; Sabrina Marsha Buharideen; Dhananjaya D; Tarek A Bismar
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

Review 2.  Molecular Crosstalk Between MYC and HIF in Cancer.

Authors:  Yanping Li; Xiao-Xin Sun; David Z Qian; Mu-Shui Dai
Journal:  Front Cell Dev Biol       Date:  2020-11-05

3.  Circ_0058106 promotes proliferation, metastasis and EMT process by regulating Wnt2b/β-catenin/c-Myc pathway through miR-185-3p in hypopharyngeal squamous cell carcinoma.

Authors:  Ce Li; Wenming Li; Shengda Cao; Jianing Xu; Ye Qian; Xinliang Pan; Dapeng Lei; Dongmin Wei
Journal:  Cell Death Dis       Date:  2021-11-09       Impact factor: 8.469

4.  Prostate cancer in omics era.

Authors:  Nasrin Gholami; Amin Haghparast; Iraj Alipourfard; Majid Nazari
Journal:  Cancer Cell Int       Date:  2022-09-05       Impact factor: 6.429

Review 5.  Cancer Stem Cells and the Tumor Microenvironment: Targeting the Critical Crosstalk through Nanocarrier Systems.

Authors:  Aadya Nayak; Neerada Meenakshi Warrier; Praveen Kumar
Journal:  Stem Cell Rev Rep       Date:  2022-07-25       Impact factor: 6.692

6.  Polymorphisms in Genes Encoding Glutathione Transferase Pi and Glutathione Transferase Omega Influence Prostate Cancer Risk and Prognosis.

Authors:  Veljko Santric; Dejan Dragicevic; Marija Matic; Milica Djokic; Marija Pljesa-Ercegovac; Tanja Radic; Sonja Suvakov; Marina Nikitovic; Vesna Stankovic; Bogomir Milojevic; Milan Radovanovic; Zoran Dzamic; Tatjana Simic; Ana Savic-Radojevic
Journal:  Front Mol Biosci       Date:  2021-04-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.